Figure 1.
All participants received the complete course of vaccination and were followed for 4 weeks after the last vaccination. * The subject lost to follow-up and was in good health when examined after the scheduled Day 365 visit.
Table 1.
Baseline characteristics of study participants.
Figure 2.
Intensity of local and systemic AE in the 7 days post-vaccination period. Given is the grade of the AE with the highest intensity at each day of follow up as shading (from grey [no AE] to dark blue [grade 3]). Local grade 2 AEs were (top down) pain, swelling, swelling, and pruritus at the injection site. Grade 3 reactions were only present as systemic reactions. They consisted of (top down) fever, fever, loss of appetite, and fever (all fevers were due to upper respiratory infection). All grade 3 AEs were judged not to be related to vaccination. Vaccinations were given on Days 0, 28, and 56.
Table 2.
Non-solicited adverse events grouped by organ system, recorded until one month after last vaccination.
Figure 3.
Antibody responses against GMZ2, GLURP, and MSP3 are shown as boxplot in the original measurement scale (Fraction of positive control).
Table 3.
Change in antigen-specific antibody concentration to GMZ2, GLURP and MSP3 after 1, 2 and 3 doses of vaccine.
Table 4.
Area under the curve IgG concentration.
Figure 4.
Results are given as GMZ2-specific per 1000 ASCs.